Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors

NCT06656390 is registered in ClinicalTrials.gov with Shanghai Allink Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT06656390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06656390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors
Lead sponsor
Shanghai Allink Biotherapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 24, 2024
Completion date
April 22, 2028
Enrollment
202 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumors